Advertisement

Agents and Actions

, Volume 28, Issue 1–2, pp 53–61 | Cite as

Rocastine (AHR-11325), a rapid acting, nonsedating antihistamine

  • J. C. Nolan
  • D. J. Stephens
  • A. G. Proakis
  • C. A. Leonard
  • D. N. Johnson
  • B. F. Kilpatrick
  • M. H. Foxwell
  • J. M. Yanni
Allergy, Histamine and Kinins

Abstract

Rocastine [AHR-11325, 2-[2-(dimethylamino)ethyl]-2,3-dihydro-4-methylpyrido-[3,2-f]-1,4-oxazepine-5(4H)-thione (E)-2-butenedioate)] is a rapid-acting, potent, nonsedating antihistamine. In guinea pigs challenged with a lethal dose of histamine, rocastine is as effective [based on 1 hr. oral, protective dose (PD50s)] as brompheniramine, chlorpheniramine, pyrilamine, and promethazine and superior to astemizole, diphenhydramine, terfenadine, and oxaomide. Rocastine has a faster onset of action than does terfenadine; rocastine being as effective with a 15 min pretreatment time (PD50=0.13 mg/kg) as it is with a 1 hr pretreatment time (PD50=0.12 mg/kg), while the 15 min PD50 of terfenadine (PD50=44.0 mg/kg) is 22 times greater than the 1 hr PD50 (PD50=1.93 mg/kg). Against aerosolized histamine, rocastine was 7.12×, 2.63×, and equipotent to pyrilamine in preventing histamine-induced prostration at pretreatment times of 1, 3, and 6 hr, respectively. Rocastine protected guinea pigs from collapse induced by aerosolized antigen; rocastine was ∼36 × more potent (based on 1 hr PD50) than diphenhydramine and as potent as oxatomide and terfenadine. Rocastine did not alter the EEG of cats at doses in vast excess (150×) of its antihistaminic dose nor did it potentiate yohimbine toxicity in mice. Further, rocastine possesses no anticholinergic, antiadrenergic, or antiserotonergic propertiesin vitro. Rocastine is a selective, nonsedating, H1-antagonist with a rapid onset of action.

Keywords

Terfenadine Yohimbine Diphenhydramine Astemizole Promethazine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    A. Nicholson and B. Stone,Antihistamines: impaired performance and the tendency to sleep. Eur. J. Pharmacol.30, 27–32 (1986).Google Scholar
  2. [2]
    T. Roehrs, E. Tietz, F. Zorick and T. Roth,Daytime sleepiness and antihistamines. Sleep7(2), 137–141 (1984).PubMedGoogle Scholar
  3. [3]
    A. Nicholson,New antihistamines free of sedative side effects. Tips8, 247–249 (1987).Google Scholar
  4. [4]
    A. Barnett, L. Iorio, W. Kreutner, S. Tozzi, H. Ahn and A. Gulbenkian,Evaluation of the CNS properties of SCH 29851, a potential nonsedating antihistamine. Agents and Actions14(5/6), 590–597 (1984).PubMedGoogle Scholar
  5. [5]
    A. Ahn and A. Barnett,Selective displacement of [3H]mepyramine from peripheral vs. central nervous system receptors by loratadine. Eur. J. Pharmacol.127, 153–155 (1986).PubMedGoogle Scholar
  6. [6]
    N. Weich and J. Martin,Absence of an effect of terfenadine on guinea pig brain histamine H 1-receptors in vivo determined by receptor binding techniques. Arzneim.-Forsch./Drug Res.32(11) 1167–1170 (1982).Google Scholar
  7. [7]
    C. Calcutt, C. Ganellin, B. Jackson, B. Leigh, D. Owen and I. Smith,Evidence for low brain penetration by the H 1-receptor antagonist temelastine (SK & F 93944). Eur. J. Pharmacol.133, 67–74 (1987).Google Scholar
  8. [8]
    E. Brown, R. Griffiths, C. Harvey and D. Owen,Pharmacological studies with SK&F 93944 (temelastine), a novel histamine H 1-receptor antagonist with negligible ability to penetrate the central nervous system. Br. J. Pharmac.87, 569–578 (1986).Google Scholar
  9. [9]
    J. Van Wauwe, F. Awouters, C. Neimegeers, F. Janssens, J. Vannueten and P. Janssen,In vivo pharmacology of astemizole, a new type of H 1-antihistaminic compound. Arch. Int. Pharmacodyn.251, 39–51 (1981).PubMedGoogle Scholar
  10. [10]
    C. Faingold and C. Berry,Effects of antihistamine agents upon the electrographic activity of the cat brain: a power spectral density study. Neuropharmacology11, 491–498 (1972).PubMedGoogle Scholar
  11. [11]
    R. Ruckart and D. Johnson,Effects of antihistaminic agents on sleep patterns in cats: A new method for detecting sedative potential. Pharmacologist25 (Abstract) 180 (1983).Google Scholar
  12. [12]
    G. Bruce, R. Tabor, M. Haimes-Bartolf and W. Kinner,Effect of AHR-11325 on lung and brain histamine receptors. Pharmacologist26 (Abstract), 97 (1984).Google Scholar
  13. [13]
    R. Ruckart, B. Turley, S. Erdle and D. Johnson,CNS effects of AHR-11325, a new nonsedative antihistamine. Pharmacologist26 (Abstract), 222 (1984).Google Scholar
  14. [14]
    C. Leonard, C. Jackson, D. Stephens, A. Proakis, R. Alphin,AHR-11325, a new antihistamine agent. Pharmacologist26 (Abstract), 221 (1984).Google Scholar
  15. [15]
    P. Anderson and H. Bergstrand,Antigen-induced bronchial anaphylaxis in actively sensitized guinea pigs: effect of longterm treatment with sodium cromoglycate and aminophylline. Br. J. Pharmacol.74, 601–609 (1981).PubMedGoogle Scholar
  16. [16]
    R. Quinton,The increase in toxicity of yohimbine induced by imipramine and other drugs in mice. Br. J. Pharmacol.21, 51–66 (1963).PubMedGoogle Scholar
  17. [17]
    J. Malick,Yohimbine potentiation as a predictor of antidepressant action. In:Antidepressants: neurochemical, behavioral and clinical perspectives. Raven Press, New York (1981).Google Scholar
  18. [18]
    J. Van Rossum,Cummulative dose-response curves. II. Techniques for the making of dose-response curves in isolated organs and the evaluation of drug parameters. Arch. int. Pharmacodyn.143, 229–330 (1963).Google Scholar
  19. [19]
    O. Arunlakshana and H. SchildSome quantitative uses of drug antagonists. Br. J. Pharmacol.14, 48–58 (1959).PubMedGoogle Scholar
  20. [20]
    R. Chang, V. Tran and S. Snyder,Histamine H 1-receptors in brain labeled with 3-H-mepyramine. Eur. J. Pharmacol.48, 463–464 (1978).PubMedGoogle Scholar
  21. [21]
    W. Clarke, L. Jones and R. Lefkowitz,Hepatic alphadrenergic receptors. J. Biol. Chem.253(17), 5975–5979 (1978).PubMedGoogle Scholar
  22. [22]
    H. Yamamura and S. Snyder,Muscarinic cholinergic binding in rat brain. PNAS, USA,71, 1725–1729 (1974).Google Scholar
  23. [23]
    J. Leysen, J. Niemegeers, J. Van Hueten and P. Laduron, [3H]Ketanserin (R 41 468), a selective 3 H-ligand for serotonin 2 receptor binding sites. Mol. Pharmacol.21, 301–314 (1982).PubMedGoogle Scholar
  24. [24]
    J. Lundeen,Computer analysis of binding data. InReceptor binding in drug research. Ed. by R.A. O'Brien, Dekker NY, 31–49 (1986).Google Scholar
  25. [25]
    C. Perrier, M. Griessen,Action of H 1 and H2 inhibitors on the response of histamine sensitive adenylate cyclase from guineapig mucosa. Eur. J. Clin. Invest.6, 113–120 (1976).PubMedGoogle Scholar
  26. [26]
    A. Gilman,A protein binding assay for adenosine 3′, 5′-monophosphate. PNAS, USA,67, 305–312 (1970).Google Scholar
  27. [27]
    J. Litchfield and F. Wilcoxon,A simplified method for evaluating dose-effect experiments. J. Pharmac. Exp. Ther.96, 99–113 (1949).Google Scholar
  28. [28]
    H. Collier and G. James,Humoral factors affecting pulmonary inflation during acute anaphylaxis in the guinea pig in vivo. Br. J. Pharmacol. Chemother.30, 283–301 (1967).Google Scholar
  29. [29]
    S. Tozzi, F. Roth and I. Tabachnick,The pharmacology of azatadine, a potential antiallergy drug. Agents Actions4(4), 264–270 (1974).PubMedGoogle Scholar
  30. [30]
    D. Richards, R. Brogden, R. Heel, t. Speight and G. Avery,Astemizole a review of its pharmacodynamic properties and therapeutic efficacy. Drugs28, 38–61 (1984a).PubMedGoogle Scholar
  31. [31]
    W. Kreutner, R. Chapman, A. Gulbenkian, M. Siegel,Antiallergic activity of loratadine, a nonsedating antihistamine. Allergy42, 57–63 (1987).PubMedGoogle Scholar
  32. [32]
    J. Van Neuten, R. Xhonneux and P. Janssen,Preliminary data on antiseratonin effects of oxatomide, a novel antiallergic compound Arch. int. Pharmacodyn.232, 217–220 (1978).PubMedGoogle Scholar
  33. [33]
    H. Cheng and J. Woodward,Antihistaminc effect of terfenadine: a new piperidine-type antihistamine. Drug Dev. Res.2, 181–196 (1982).Google Scholar
  34. [34]
    D. Richards, R. Brogden, R. Heel, T. Speight and G. Avery,Oxatomide a review of its pharmacodynamic properties and therapeutic efficacy. Drugs27, 210–231 (1984b).PubMedGoogle Scholar
  35. [35]
    F. Awouters, C. Niemegeers, P. Janssen, M. Janssen, J. Van Denberk, L. Kennis, M. Van Der Aa and A. Van Heertum,Oxatomide: the prototype of a chemical series of compounds inhibiting both the release and the effects of allergic mediators. ACS Symposium Series118, 179–208 (1979).Google Scholar
  36. [36]
    C. Carter, N. Wojciechowski, J. Hayes, V. Skoutakis and L. Rickman,Terfenadine, a nonsedating antihistamine. Drug. Intell. Clin. Phar.19, 812–817 (1985).Google Scholar

Copyright information

© Birkhäuser Verlag 1989

Authors and Affiliations

  • J. C. Nolan
    • 1
  • D. J. Stephens
    • 1
  • A. G. Proakis
    • 1
  • C. A. Leonard
    • 1
  • D. N. Johnson
    • 1
  • B. F. Kilpatrick
    • 1
  • M. H. Foxwell
    • 1
  • J. M. Yanni
    • 1
  1. 1.Pharmacology DepartmentA.H. Robins Co.RichmondUSA

Personalised recommendations